Overview

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Status:
Active, not recruiting
Trial end date:
2022-07-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation